ENMD-2076
ENMD-2076 is a pharmaceutical drug with 8 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 8 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
5
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
8 of 8 finished
0.0%
0 ended early
0
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma
Study of ENMD-2076 in Patients With Multiple Myeloma
A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer
A Study of ENMD-2076 in Ovarian Clear Cell Cancers
Clinical Trials (8)
A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma
Study of ENMD-2076 in Patients With Multiple Myeloma
A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer
A Study of ENMD-2076 in Ovarian Clear Cell Cancers
Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies
All 8 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 8